Pharmaceutical giant Pfizer finalizes a licensing deal with 3SBio to expand access to their medical products in China.
Pfizer Expands Oncology Portfolio with Exclusive Rights to Promising Bispecific Antibody
In a significant move to advance its oncology portfolio, Pfizer Inc. (NYSE: PFE) has announced a global licensing agreement (excluding China initially) with 3SBio. This agreement grants Pfizer exclusive rights for the development, manufacturing, and commercialization of SSGJ-707, a bispecific antibody targeting PD-1 and VEGF, which is being developed on 3SBio's proprietary CLF2 platform.
Under the terms of the agreement, 3SBio will receive a payment of $1.25 billion and a $100 million equity investment from Pfizer. Pfizer also has an option to extend the license to include exclusive rights in China by paying up to $150 million in option payments.
SSGJ-707 is currently undergoing clinical trials in China for non-small cell lung cancer (NSCLC), metastatic colorectal cancer, and gynecological tumors. Positive interim Phase 2 results evaluating the safety and efficacy of SSGJ-707 as monotherapy in patients with advanced NSCLC were recently presented at the American Society of Clinical Oncology (ASCO) Annual Meeting.
Pfizer plans to initiate the first global Phase 3 studies in the U.S. with trial sites planned across the U.S. and internationally, focusing on NSCLC and other solid tumors. The drug substance for SSGJ-707 will be manufactured in Sanford, North Carolina, and the drug product in McPherson, Kansas.
Pfizer's Chief Scientific Officer highlighted that SSGJ-707 is an important candidate combining two key cancer targets (PD-1 and VEGF) and complements Pfizer’s oncology portfolio, especially their antibody-drug conjugate pipeline. The acquisition underscores Pfizer’s commitment to advancing innovative cancer therapies.
However, it's important to note that the information contained in this release involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied. These risks and uncertainties include, but are not limited to, the ability to realize the anticipated benefits of the transaction, successful integration of the licensed asset with Pfizer's business, disruption from the transaction, negative effects on Pfizer's stock and operating results, significant transaction costs, litigation and regulatory actions, manufacturing capabilities or capacity, industry, market, business, economic, political or regulatory conditions, future exchange and interest rates, risks and uncertainties related to issued or future executive orders or new, changes in, laws, regulations or policy, changes in tax and other laws, regulations, rates and policies, business effects and uncertainties, competitive developments, uncertainties regarding the commercial success of SSGJ-707 and Pfizer's commercialized and pipeline products, risks associated with preliminary or interim data, risks related to regulatory authorities' decisions, the impact of COVID-19, and uncertainties regarding the impact of the transaction on Pfizer's business and prospects.
A further description of risks and uncertainties can be found in Pfizer's Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and in its subsequent reports on Form 10-Q, all of which are filed with the U.S. Securities and Exchange Commission and available at www.sec.gov and www.Pfizer.com.
Pfizer Oncology focuses on delivering transformative therapies in some of the world's most common cancers, including breast cancer, genitourinary cancer, hematology-oncology, and thoracic cancers, which includes lung cancer. The acquisition of exclusive rights for the development, manufacturing, and commercialization of SSGJ-707 is a strategic move to strengthen Pfizer's innovative Oncology portfolio.
[1] Pfizer Press Release, "Pfizer and 3SBio Enter into Global Licensing Agreement for Bispecific Antibody SSGJ-707," July 24, 2025. [2] 3SBio Press Release, "3SBio Announces Global Licensing Agreement with Pfizer for Bispecific Antibody SSGJ-707," July 24, 2025. [3] BusinessWire, "Pfizer and 3SBio Enter into Global Licensing Agreement for Bispecific Antibody SSGJ-707," July 24, 2025. [4] Reuters, "Pfizer Acquires Exclusive Rights to Develop, Manufacture, and Commercialise 3SBio's SSGJ-707," July 24, 2025. [5] BioPharma Dive, "Pfizer Expands Oncology Portfolio with 3SBio's Bispecific Antibody SSGJ-707," July 24, 2025.
- The agreement between Pfizer and 3SBio, involving a promising bispecific antibody called SSGJ-707, signifies a strategic expansion of Pfizer's oncology portfolio within the healthcare and wellness industry.
- Pfizer's investment in the development of SSGJ-707, which targets medical conditions such as non-small cell lung cancer, metastatic colorectal cancer, and gynecological tumors, is expected to impact the finance and business sectors by potentially leading to innovative cancer therapies in the global market.
- The collaborative efforts between Pfizer and 3SBio highlight the commitment of both companies to advance scientific research, particularly in the field of oncology, while addressing potential uncertainties and risks associated with the development and commercialization of new therapeutics.
